Why Science? | Nucleic Acid Therapeutics Initiative

Official NATi and A*STAR sources describe a platform connecting research, clinical translation, commercialisation and preparedness. NATi acts as a translational platform, accelerator and nexus across researchers, clinicians, industry and investors.

RNA medicines can instruct cells, reduce selected messages or alter how genetic information is processed. Their promise depends on sequence design, chemistry, delivery, distribution, immune response and controlled manufacture working together. The practical capability is institutional literacy. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. NATi and its authorised partners control current programmes, funding and released results; ethics bodies, regulators, trial sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “NATi is Singapore’s national RNA-medicine platform” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: National-platform status does not establish efficacy for any candidate.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Next chapter

DNA stores genetic information while cells transcribe selected regions into RNA. Messenger RNA can guide protein production, and other RNAs help regulate processing, translation and degradation. Therapeutic designs intervene in these information flows.

Nucleic acids are information-rich molecules but they are also physical materials that can degrade or trigger biological responses. Formulation and quality attributes therefore matter alongside the encoded or complementary sequence. The practical capability is molecular-biology literacy. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. NATi and its authorised partners control current programmes, funding and released results; ethics bodies, regulators, trial sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “DNA and RNA move biological information” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: A simplified central-dogma diagram does not capture every regulatory pathway.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Therapeutic mRNA delivers a sequence that cellular machinery translates into a protein. Sequence, untranslated regions, cap, tail, purity and delivery influence expression. Because the molecule is transient, dose and duration require empirical evidence.

Delivery is part of the therapy. A potent RNA sequence cannot act if it fails to reach the relevant cells, escape internal compartments or persist for the needed time without unacceptable effects. The practical capability is mRNA reasoning. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. NATi and its authorised partners control current programmes, funding and released results; ethics bodies, regulators, trial sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “mRNA can provide temporary instructions” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: Protein expression in cells does not establish clinical benefit or safety.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Small interfering RNA can guide cellular machinery toward a complementary RNA target and promote its degradation. Potency depends on target accessibility, sequence and delivery. Partial complementarity can contribute to unintended effects.

Translation connects molecular biology with analytical science, pharmacology, manufacturing, clinical development and regulation. Evidence should remain stage-labelled from discovery through early clinical learning. The practical capability is RNA-interference literacy. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. NATi and its authorised partners control current programmes, funding and released results; ethics bodies, regulators, trial sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “siRNA can reduce selected messages” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: A predicted match does not prove selective knockdown in relevant tissue.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Antisense oligonucleotides bind selected RNA sequences and may change splicing, block translation or recruit degradation mechanisms depending on design chemistry. Cellular localisation and target turnover matter.

RNA medicines can instruct cells, reduce selected messages or alter how genetic information is processed. Their promise depends on sequence design, chemistry, delivery, distribution, immune response and controlled manufacture working together. The practical capability is antisense literacy. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. NATi and its authorised partners control current programmes, funding and released results; ethics bodies, regulators, trial sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Antisense oligonucleotides can alter RNA fate” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: Binding to RNA does not guarantee the intended functional change.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Designers consider target isoforms, conserved regions, secondary structure, sequence motifs and off-target candidates. Computational screening narrows options while experiments test activity. Controls separate sequence-specific effects from delivery or chemistry effects.

Nucleic acids are information-rich molecules but they are also physical materials that can degrade or trigger biological responses. Formulation and quality attributes therefore matter alongside the encoded or complementary sequence. The practical capability is sequence-design reasoning. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. NATi and its authorised partners control current programmes, funding and released results; ethics bodies, regulators, trial sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Sequence design balances mechanism and specificity” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: A favourable in-silico score is not biological validation.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Backbone, sugar and base modifications can improve stability, affinity or immune profile. They may also change toxicity, distribution or manufacturing. Each molecule is a defined chemical entity whose impurities and variants need analytical control.

Delivery is part of the therapy. A potent RNA sequence cannot act if it fails to reach the relevant cells, escape internal compartments or persist for the needed time without unacceptable effects. The practical capability is nucleic-acid chemistry. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. NATi and its authorised partners control current programmes, funding and released results; ethics bodies, regulators, trial sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Chemical modification changes behaviour” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: A modification helpful in one modality may not transfer to another.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Naked nucleic acids face degradation and limited cellular entry. Lipid nanoparticles, conjugates or other carriers can protect cargo and influence distribution. Particle composition, size, charge and surface properties interact with biological fluids and tissues.

Translation connects molecular biology with analytical science, pharmacology, manufacturing, clinical development and regulation. Evidence should remain stage-labelled from discovery through early clinical learning. The practical capability is delivery-science literacy. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. NATi and its authorised partners control current programmes, funding and released results; ethics bodies, regulators, trial sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Delivery determines which cells receive the medicine” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: Efficient uptake by one cell type does not prove delivery to the intended organ in vivo.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

After uptake, a therapeutic may remain trapped in endosomes, be degraded or reach the wrong cellular compartment. Endosomal escape and release are often inefficient. Assays should distinguish total uptake from functional delivery to the site of action.

RNA medicines can instruct cells, reduce selected messages or alter how genetic information is processed. Their promise depends on sequence design, chemistry, delivery, distribution, immune response and controlled manufacture working together. The practical capability is cellular-trafficking reasoning. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. NATi and its authorised partners control current programmes, funding and released results; ethics bodies, regulators, trial sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Intracellular trafficking can limit activity” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: High fluorescence inside a cell may represent trapped material rather than active delivery.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Teams measure where the RNA and carrier travel, how long they persist and which cells they enter. Blood concentration may not equal target-tissue exposure. Labels and assays can alter or incompletely represent intact functional material.

Nucleic acids are information-rich molecules but they are also physical materials that can degrade or trigger biological responses. Formulation and quality attributes therefore matter alongside the encoded or complementary sequence. The practical capability is biodistribution literacy. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. NATi and its authorised partners control current programmes, funding and released results; ethics bodies, regulators, trial sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Biodistribution connects formulation to exposure” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: A tissue signal does not automatically prove intracellular activity.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Molecular assays can measure RNA abundance, protein expression or splice form; functional assays test a downstream phenotype. Orthogonal methods reduce dependence on one readout. Dose-response and time-course data clarify potency and duration.

Delivery is part of the therapy. A potent RNA sequence cannot act if it fails to reach the relevant cells, escape internal compartments or persist for the needed time without unacceptable effects. The practical capability is mechanistic assay design. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. NATi and its authorised partners control current programmes, funding and released results; ethics bodies, regulators, trial sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Assays should test mechanism and consequence” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: A molecular change is not automatically a meaningful biological outcome.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Cells recognise features of foreign nucleic acids and carriers. Immune activation may support a vaccine purpose or create unwanted inflammation for another therapy. Sequence, chemistry, purity, route and dose influence responses.

Translation connects molecular biology with analytical science, pharmacology, manufacturing, clinical development and regulation. Evidence should remain stage-labelled from discovery through early clinical learning. The practical capability is immunology literacy. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. NATi and its authorised partners control current programmes, funding and released results; ethics bodies, regulators, trial sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Innate immunity can be both signal and risk” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: One cytokine panel cannot rule out every immune effect.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Sequence-dependent off-target binding, chemistry-related effects, carrier effects and exaggerated intended pharmacology can all matter. Teams combine computational review, molecular assays, cells and in-vivo studies with exposure context.

RNA medicines can instruct cells, reduce selected messages or alter how genetic information is processed. Their promise depends on sequence design, chemistry, delivery, distribution, immune response and controlled manufacture working together. The practical capability is safety reasoning. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. NATi and its authorised partners control current programmes, funding and released results; ethics bodies, regulators, trial sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Off-target and safety evidence need several layers” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: Absence of a predicted off-target is not proof of zero unintended activity.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Pharmacokinetics, biodistribution and pharmacodynamics connect administered dose with tissue exposure, target engagement and duration. Repeated dosing may change response or immune profile. A dose should be interpreted with the formulation and route.

Nucleic acids are information-rich molecules but they are also physical materials that can degrade or trigger biological responses. Formulation and quality attributes therefore matter alongside the encoded or complementary sequence. The practical capability is PK-PD literacy. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. NATi and its authorised partners control current programmes, funding and released results; ethics bodies, regulators, trial sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Pharmacology links dose to molecular and functional response” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: An administered mass does not describe the active amount reaching target cells.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

RNA synthesis, purification, formulation and fill-finish create quality attributes such as sequence identity, integrity, capping or conjugation, potency, particle properties, impurities and sterility as relevant. Process changes require comparability evidence.

Delivery is part of the therapy. A potent RNA sequence cannot act if it fails to reach the relevant cells, escape internal compartments or persist for the needed time without unacceptable effects. The practical capability is CMC reasoning. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. NATi and its authorised partners control current programmes, funding and released results; ethics bodies, regulators, trial sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Manufacturing controls identity, purity and consistency” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: A correct nominal sequence does not establish a consistent drug product.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Temperature, light, nucleases, oxidation, aggregation or container interactions can affect RNA products and carriers. Stability programmes define storage and shelf life. Clinical studies then use reviewed protocols, consent, monitoring and stage-appropriate endpoints.

Translation connects molecular biology with analytical science, pharmacology, manufacturing, clinical development and regulation. Evidence should remain stage-labelled from discovery through early clinical learning. The practical capability is translation literacy. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. NATi and its authorised partners control current programmes, funding and released results; ethics bodies, regulators, trial sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Stability and clinical translation preserve the product and question” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: A stable formulation or early clinical signal does not guarantee approval.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter · Next chapter

Archive target rationale, sequence and chemistry, formulation lot, analytical identity, potency, delivery, biodistribution, immune findings, PK-PD, safety, manufacturing stage, stability and regulatory decisions. Students can model sequences safely while qualified teams control laboratory and clinical work.

RNA medicines can instruct cells, reduce selected messages or alter how genetic information is processed. Their promise depends on sequence design, chemistry, delivery, distribution, immune response and controlled manufacture working together. The practical capability is RNA-therapeutics career preparation. Keep the question, method, controls, observation, uncertainty, review and next decision in one evidence receipt. That record makes progress visible without enlarging the claim beyond the stage reached. NATi and its authorised partners control current programmes, funding and released results; ethics bodies, regulators, trial sponsors and clinicians control studies and patient care.

Put this into practice by turning the idea into a small, reviewable action: Build a dated evidence card for “Keep an RNA-medicine evidence receipt” with the question, method, observation, limitation and next test. Then ask what the resulting note or artefact actually demonstrates. A useful record names context, source or instruction, action, observation, interpretation and uncertainty. It also preserves this limit: Current funding calls, studies and products must be verified with official owners and authorities.

An evidence check keeps confidence proportional to what the work can show. Separate the original observation or official statement from the learner’s explanation. Record feedback and any revision. If information is missing, write “not shown” or “not yet known” rather than guessing. That honest gap can become the next question.

Contents · Previous chapter